Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21686701 | 0.83 | KDM4E (0.49) | KMT2AKDM4EUSP2HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL6344221 | 0.81 | KDM4E (0.48) | KMT2AKDM4EUSP2HPGDHSD17B10 | |
| SCHEMBL21686412 | 0.79 | HPGD (0.51) | KDM4EUSP2HPGDHSD17B10TTR | |
| SCHEMBL21686408 | 0.78 | IDO1 (0.55) | KMT2AKDM4EHPGDHSD17B10 | |
| SCHEMBL28856671 | 0.76 | BRD4 (0.52) | BRD4PTGS2 | |
| SCHEMBL21686414 | 0.75 | BRD4 (0.47) | BRD4KMT2AKDM4EUSP2HPGD | |
| SCHEMBL21686770 | 0.75 | HPGD (0.47) | KMT2AKDM4EUSP2HPGDHSD17B10 | |
| SCHEMBL24025727 | 0.75 | BRD4 (0.49) | BRD4CTNNB1KMT2AFFAR4HSD17B10 | |
| SCHEMBL21686700 | 0.74 | KMT2A (0.51) | KMT2AFFAR4KDM4EUSP2HPGD | |
| SCHEMBL16042338 | 0.74 | BRD4 (0.81) | BRD4CTNNB1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-20 | — | — | US | disclosed |
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200039963-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | BRD4 78/4885CTNNB1 780/4885KMT2A 66/4885 |
| US-20200039963-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | BMI1, EZH2, CBX3 | BRD4 78/4885CTNNB1 780/4885KMT2A 66/4885 |
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | BMI1, EZH2, CBX3 | BRD4 78/4885CTNNB1 780/4885KMT2A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.